ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Kronos buys Gilead’s SYK inhibitors

by Lisa M. Jarvis
July 25, 2020 | APPEARED IN VOLUME 98, ISSUE 29

 

09829-buscon16-entos.jpg

Gilead Sciences has licensed its spleen tyrosine kinase (SYK) inhibitors to the oncology-focused biotech firm Kronos Bio. The collection of small molecules includes entospletinib, which has already gone through multiple Phase II studies in blood cancers, and lanraplenib, which has completed Phase II trials in lupus and other autoimmune diseases. Kronos CEO Norbert Bischofberger is very familiar with the compound portfolio, having previously led R&D at Gilead. Kronos was founded in 2017 and was one of C&EN’s 10 Start-Ups to Watch in 2018.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment